{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:06Z","timestamp":1791908406183,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["0065353"],"award-info":[{"award-number":["0065353"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to investigate the feasibility of nurse-led consultations based on ePRO for women with endometrial or ovarian cancer receiving chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a\u00a0prospective single-cohort feasibility study. The patients responded to weekly ePRO using the Elekta Kaiku platform, which was adapted to Danish. At selected time points during chemotherapy, nurses conducted nurse-led consultations replacing physicians. The primary outcome was the patient completion rate of ePRO reporting in the Elekta Kaiku platform. Secondary outcomes included assessing safety, acceptability, practicability, usability, patient satisfaction with ePRO, and patient symptom burden.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty patients were included, with a mean age of 59\u00a0years. A total of 320 ePRO reports were received, equivalent to an ePRO response of 18 times per patient during six cycles of chemotherapy. The results showed a high weekly completion rate (87%), high patient satisfaction with ePRO, and a continuous high symptom burden. Nurse-led consultations achieved a success rate of 55% in adhering to scheduled appointments. The primary contributing factors to this issue were the inadequate internal workflows and the complex symptom burden experienced by the patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study indicates that weekly ePRO reporting in conjunction with nurse-led consultations may be feasible in this population. The use of ePRO revealed a high level of symptoms reported by patients throughout the treatment cycles. The results emphasize the importance of clinicians in proactively and systematically intervening at an early stage to prevent symptom escalation. However, the small sample size limits the generalizability of this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>This study was registered at the Capital Region of Denmark (P-2021\u2013179) and approved the 10\/03\/2021. ClinicalTtrials.gov\u00a0ID: NTCC04945187.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09875-y","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:15:34Z","timestamp":1758147334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systematic nurse-led consultations based on electronic patient-reported outcomes for women with endometrial or ovarian cancer during chemotherapy\u2014a feasibility study"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1507-1130","authenticated-orcid":false,"given":"Mille Guldager","family":"Christiansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-5372","authenticated-orcid":false,"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3040-8384","authenticated-orcid":false,"given":"Mary","family":"Jarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-9889","authenticated-orcid":false,"given":"Anders","family":"Tolver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6352-2957","authenticated-orcid":false,"given":"Hjalte S\u00f8berg","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-1010","authenticated-orcid":false,"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-4674","authenticated-orcid":false,"given":"Karin","family":"Piil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"9875_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"9875_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I et al (2021) ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12\u201339","journal-title":"Int J Gynecol Cancer"},{"key":"9875_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40271-019-00393-8","volume":"13","author":"ML Martin","year":"2020","unstructured":"Martin ML, Halling K, Eek D et al (2020) \u201cLower abdominal pains, as if I was being squeezed\u2026in a clamp\u201d: a qualitative analysis of symptoms, patient-perceived side effects and impacts of ovarian cancer. Patient 13:189\u2013200","journal-title":"Patient"},{"key":"9875_CR4","first-page":"2215","volume":"23","author":"L Stafford","year":"2015","unstructured":"Stafford L, Judd F, Gibson P et al (2015) Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer 23:2215\u20132224","journal-title":"Support Care Cancer"},{"key":"9875_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijnurstu.2018.05.014","volume":"86","author":"A Charalambous","year":"2018","unstructured":"Charalambous A, Wells M, Campbell P et al (2018) A scoping review of trials of interventions led or delivered by cancer nurses. Int J Nurs Stud 86:36\u201343","journal-title":"Int J Nurs Stud"},{"issue":"9","key":"9875_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"M Di Maio","year":"2022","unstructured":"Di Maio M, Basch E, Denis F et al (2022) The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann Oncol 33(9):878\u2013892. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.007","journal-title":"Ann Oncol"},{"key":"9875_CR7","first-page":"1323","volume":"25","author":"D Howell","year":"2017","unstructured":"Howell D, Harth T, Brown J et al (2017) Self-management education interventions for patients with cancer: a systematic review. Support Care Cancer 25:1323\u20131355","journal-title":"Support Care Cancer"},{"key":"9875_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejon.2017.05.007","volume":"29","author":"A Serena","year":"2017","unstructured":"Serena A, Dwyer A, Peters S et al (2017) Feasibility of advanced practice nursing in lung cancer consultations during early treatment: a phase II study. Eur J Oncol Nurs 29:106\u2013114","journal-title":"Eur J Oncol Nurs"},{"key":"9875_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2022.102203","volume":"61","author":"HH Gyldenvang","year":"2022","unstructured":"Gyldenvang HH, Christiansen MG, Jarden M et al (2022) Experiences and perspectives of patients and clinicians in nurse-led clinics in an oncological setting: a sequential multi-methods study. Eur J Oncol Nurs 61:102203","journal-title":"Eur J Oncol Nurs"},{"key":"9875_CR10","unstructured":"FDA (2209) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. u.s. department of health and human services, food and drug administration, center for drug evaluation and research (CDER), Center for biologics evaluation and research (CBER), Center for devices and radiological health (CDRH). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measuresuse-medical-product-development-support-labeling-claims"},{"key":"9875_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-022-01767-3","author":"TR Kiderlen","year":"2022","unstructured":"Kiderlen TR, Schnack A, de Wit M (2022) Essential barriers and considerations for the implementation of electronic patient-reported outcome (ePRO) measures in oncological practice: contextualizing the results of a feasibility study with existing literature. J Public Health. https:\/\/doi.org\/10.1007\/s10389-022-01767-3","journal-title":"J Public Health"},{"key":"9875_CR12","doi-asserted-by":"publisher","DOI":"10.2196\/15588","volume":"3","author":"J Meirte","year":"2020","unstructured":"Meirte J, Hellemans N, Anthonissen M et al (2020) Benefits and disadvantages of electronic patient-reported outcome measures: systematic review. JMIR Perioper Med 3:e15588","journal-title":"JMIR Perioper Med"},{"key":"9875_CR13","doi-asserted-by":"publisher","unstructured":"Absolom K, Shearsmith L, Holmes et al\u00a0(2021) Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. J Clin Oncol 39(7):734\u2013747.\u00a0https:\/\/doi.org\/10.1200\/JCO.20.02015","DOI":"10.1200\/JCO.20.02015"},{"key":"9875_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09817-5","volume":"22","author":"F Kennedy","year":"2022","unstructured":"Kennedy F, Shearsmith L, Holmes M et al (2022) Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study. BMC Cancer 22:1\u201315","journal-title":"BMC Cancer"},{"key":"9875_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2022.09.010","volume":"167","author":"M Wickline","year":"2022","unstructured":"Wickline M, Wolpin S, Cho S et al (2022) Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: a mixed methods study. Gynecol Oncol 167:239\u2013246","journal-title":"Gynecol Oncol"},{"key":"9875_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/0284186X.2022.2046850","volume":"61","author":"MG Christiansen","year":"2022","unstructured":"Christiansen MG, Jarden M, Bager L et al (2022) SystematiC nurse-led cONsultations based oN Electronic patient-reported outcome among women with ovarian- or endometrial Cancer during chemoTherapy \u2013 protocol for the CONNECT study. Acta Oncol (Madr) 61:602\u2013607","journal-title":"Acta Oncol (Madr)"},{"key":"9875_CR17","doi-asserted-by":"publisher","unstructured":"Eldridge SM, Chan CL, Campbell MJ et al (2016) CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 355:i5239. https:\/\/doi.org\/10.1136\/bmj.i5239","DOI":"10.1136\/bmj.i5239"},{"key":"9875_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tipsro.2021.12.001","volume":"21","author":"PK M\u00f8ller","year":"2022","unstructured":"M\u00f8ller PK, Pappot H, Bernchou U et al (2022) Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy \u2013 a prospective pilot study. Technical Innovations & Patient Support in Radiation Oncology 21:8\u201315","journal-title":"Technical Innovations & Patient Support in Radiation Oncology"},{"key":"9875_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MLR.0000000000001664","volume":"60","author":"JA Teresi","year":"2022","unstructured":"Teresi JA, Yu X, Stewart AL et al (2022) Guidelines for designing and evaluating feasibility pilot studies. Med Care 60:95\u2013103","journal-title":"Med Care"},{"key":"9875_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","volume":"36","author":"DJ Bowen","year":"2009","unstructured":"Bowen DJ, Kreuter M, Spring B et al (2009) How we design feasibility studies. Am J Prev Med 36:452\u2013457","journal-title":"Am J Prev Med"},{"key":"9875_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-018-0900-4","volume":"16","author":"LK Tolstrup","year":"2018","unstructured":"Tolstrup LK, Pappot H, Zangger G et al (2018) Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form. Health Qual Life Outcomes 16:1\u20137","journal-title":"Health Qual Life Outcomes"},{"key":"9875_CR22","unstructured":"Elekta Kaiku. https:\/\/www.elekta.com\/products\/life-sciences\/elekta-kaiku\/. Accessed 20 Mar 2025"},{"key":"9875_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-023-00611-w","volume":"7","author":"MG Christiansen","year":"2023","unstructured":"Christiansen MG, Pappot H, Jensen PT et al (2023) A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy. J Patient Rep Outcomes 7:1\u201313","journal-title":"J Patient Rep Outcomes"},{"key":"9875_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA et al (2015) Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051\u20131059","journal-title":"JAMA Oncol"},{"key":"9875_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/0284186X.2023.2194031","volume":"62","author":"LK Tolstrup","year":"2023","unstructured":"Tolstrup LK, Als AB, Carus A et al (2023) The iBLAD app protocol\u2013a national, exploratory study on a multimodality smartphone app in bladder cancer for better understanding symptoms, quality of life and need for supportive care. Acta Oncol (Madr) 62:329\u2013333","journal-title":"Acta Oncol (Madr)"},{"key":"9875_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"176","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas A, Setser A, Rusch V, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CRR (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 176:176\u2013181","journal-title":"Semin Radiat Oncol"},{"key":"9875_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208","journal-title":"J Biomed Inform"},{"key":"9875_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch E, Becker C, Rogak LJ et al (2021) Composite grading algorithm for the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials 18:104\u2013114","journal-title":"Clin Trials"},{"key":"9875_CR29","unstructured":"PRO-CTCAE. PRO-CTCAE\u00ae Measurement System website. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"9875_CR30","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical A","year":"2013","unstructured":"World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194","journal-title":"JAMA"},{"key":"9875_CR31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","volume":"30","author":"S Koole","year":"2020","unstructured":"Koole S, Van Stein R, Sikorska K et al (2020) Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer 30:888\u2013892","journal-title":"Int J Gynecol Cancer"},{"key":"9875_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.csbj.2023.11.054","volume":"24","author":"H Pappot","year":"2024","unstructured":"Pappot H, Assam Taarnh\u00f8j G, Bentsen L et al (2024) Patient-reported outcomes used actively in cancer patients undergoing antineoplastic treatment: a mini-review of the Danish landscape. Comput Struct Biotechnol J 24:23\u201330","journal-title":"Comput Struct Biotechnol J"},{"key":"9875_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12912-022-01104-9","volume":"21","author":"M Skorstad","year":"2022","unstructured":"Skorstad M, Vistad I, Fegran L et al (2022) Nurse-led consultations reinforced with eHealth technology: a qualitative study of the experiences of patients with gynecological cancer. BMC Nurs 21:1\u201310","journal-title":"BMC Nurs"},{"key":"9875_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103658","volume":"173","author":"AT Lutz","year":"2022","unstructured":"Lutz AT, Griza A, Machado GM et al (2022) Patient reported outcomes in the daily practice in clinical oncology: a systematic review. Crit Rev Oncol Hematol 173:103658. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103658","journal-title":"Crit Rev Oncol Hematol"},{"key":"9875_CR35","doi-asserted-by":"publisher","unstructured":"Tolstrup LK, Bastholt L, Dieperink KB et al. The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. J Patient Rep Outcomes. 2020 Oct 30;4(1):88. doi: 10.1186\/s41687-020-00255-0. PMID: 33125537; PMCID: PMC7599285. https:\/\/doi.org\/10.1186\/s41687-020-00255-0","DOI":"10.1186\/s41687-020-00255-0"},{"key":"9875_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ygyno.2021.12.006","volume":"164","author":"VL Beesley","year":"2022","unstructured":"Beesley VL, Ross TL, King MT et al (2022) Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (measure of ovarian symptoms and treatment concerns). Gynecol Oncol 164:437\u2013445","journal-title":"Gynecol Oncol"},{"key":"9875_CR37","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A et al (2020) The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol 31:1148\u20131159","journal-title":"Ann Oncol"},{"key":"9875_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jamiaopen\/ooz042","volume":"2","author":"E Austin","year":"2019","unstructured":"Austin E, LeRouge C, Hartzler AL et al (2019) Opportunities and challenges to advance the use of electronic patient-reported outcomes in clinical care: a report from AMIA workshop proceedings. JAMIA Open 2:407\u2013410","journal-title":"JAMIA Open"},{"key":"9875_CR39","doi-asserted-by":"publisher","unstructured":"Basch E, Rocque G, Mody G et al (2023) Tenets for implementing electronic patient-reported outcomes for remote symptom monitoring during cancer treatment. JCO Clin Cancer Inform 7:e2200187.\u00a0https:\/\/doi.org\/10.1200\/CCI.22.00187","DOI":"10.1200\/CCI.22.00187"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09875-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T03:39:23Z","timestamp":1760672363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09875-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9875"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09875-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Capital Region of Denmark (P-2021\u2013179) (10\/03\/2021). The Department of Medico Technology in the Capital Region of Denmark approved the utilization of the Elekta Kaiku platform. Ethical review and approval were waived for this study due to Danish law at the time of the initiation of the study. This study is registered on Clinicaltrial.gov, Identifier: NTC04945187.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Prior to their participation, all participants were provided with information regarding the publication and future use of the data, as well as the measures taken to ensure confidentiality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"858"}}